Importantly, our highly consistent findings based on pharmacological and genetic inhibition of the GR in attenuating proteinuria in three animal models strongly support that specific inactivation or antagonism of the GR in proteinuric diseases can be used to improve nephrotic syndrome caused by non-inflammatory glomerular disease. The gene discussed is NR3C1; the disease is nephrotic syndrome.